Toronto, Ontario — September 15, 2026 — Leads & Copy — HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF), a healthcare artificial intelligence company focused on preventative care, has announced significant new research demonstrating the clinical performance and real-world impact of its proprietary DARWEN™ AI platform. Studies accepted for presentation or publication across 12 medical, health informatics, artificial intelligence, and health economics forums in the fall of 2026 highlight DARWEN™’s ability to translate healthcare-specific AI into clinically relevant outcomes.
The research showcases DARWEN™’s advantages over leading general-purpose AI models in areas such as clinical summarization and treatment-plan generation. It also demonstrates measurable improvements in the identification and treatment optimization of patients with unmet clinical needs.
DARWEN™ AI, HEALWELL’s patented and clinically validated platform, transforms complex healthcare data into actionable knowledge. It powers features like SMART Search, SMART Summary, and SMART Patient ID, designed to help clinicians efficiently find critical information, understand patient histories, and identify patients requiring earlier intervention.
New research presented at AMIA 2026 indicates that HEALWELL’s DARWEN™ AI-powered SMARTSuite outperformed published benchmarks for OpenAI’s GPT, DeepSeek, and Llama in clinical summarization accuracy. Across three key evaluation measures – ROUGE-1, ROUGE-2, and ROUGE-L – DARWEN™ showed an average improvement of 43% in ROUGE-1, 21% in ROUGE-2, and 43% in ROUGE-L compared to the evaluated models.
Further research, accepted for oral presentation at AI-MEDX 2026, revealed that DARWEN™ achieved nearly 50% higher treatment-plan accuracy than a leading general-purpose AI model in blinded clinician reviews. This resulted in more clinically specific outputs, including precise drug and dosage recommendations.
A separate study published in the Canadian Journal of Cardiology demonstrated the real-world impact of DARWEN™ AI-powered SMART Patient ID. The research identified over 4,100 heart failure patients not receiving guideline-directed medical therapy, facilitating targeted clinical interventions and contributing to a 70% improvement in treatment optimization within six months. These findings underscore the potential of AI-powered patient identification to support proactive, evidence-based care for undertreated populations.
Aaron Leibtag, Head of Global Health Systems AI Strategy at HEALWELL and Co-Founder of Pentavere, stated that DARWEN™’s ongoing clinical and scientific validation coincides with its growing commercial traction. He noted that outperforming leading foundation models while demonstrating real-world patient impact validates HEALWELL’s strategic approach. Leibtag cited recent deployments, including a multi-year rollout of DARWEN™-powered SMART Search and SMART Summary across Iowa’s statewide Health Information Exchange and DARWEN™-powered clinical trial matching through WELLTRUST™’s network, as examples of HEALWELL’s strategy to translate scientific differentiation into commercial scale.
Dr. Christopher Pettengell, Chief Medical Officer of HEALWELL, emphasized that the critical question for clinical AI is its ability to consistently identify accurate information, maintain clinical context, and provide the specificity clinicians need to act. He reiterated that outperforming established AI models and demonstrating real-world patient impact validates the company’s strategy of building evidence before scaling across health systems and life sciences. Pettengell added that upcoming peer-reviewed presentations and publications will further support the efficacy of purpose-built, clinically validated AI over general-purpose approaches, reinforcing DARWEN™’s position as a differentiated clinical intelligence AI platform.
HEALWELL’s fall 2026 scientific program includes research accepted at 12 global forums, such as AMIA 2026, AI-MEDX 2026, EADV 2026, ACG 2026, The Menopause Society 2026, ISPOR Europe 2026, and the Canadian Cardiovascular Congress. These studies span women’s health, dermatology, inflammatory bowel disease, oncology, heart failure, and rare diseases, showcasing DARWEN™’s versatility in patient identification, clinical decision support, and research. The program also involves collaborations with leading pharmaceutical companies including AstraZeneca, Bayer, Galderma, UCB, Takeda, Arcutis, and Merck.
The company’s progression from scientific validation to enterprise deployment and commercial scale is evidenced by its fall scientific program and recent commercial activities. HEALWELL anticipates sharing more details on individual studies as they are presented and published.
About HEALWELL AI
HEALWELL AI is a healthcare artificial intelligence company dedicated to preventative care, aiming to enhance healthcare and save lives through early disease identification and detection. Utilizing proprietary technology, the company develops and commercializes advanced clinical decision support systems to assist healthcare providers in detecting rare and chronic diseases, improving practice efficiency, and enhancing patient health outcomes. HEALWELL’s strategy involves developing and acquiring complementary technology and clinical sciences capabilities. The company is publicly traded on the Toronto Stock Exchange under the symbol “AIDX” and on the OTC Exchange under the symbol “HWAIF”.
Source: HEALWELL AI Inc.
